Literature DB >> 19411684

Responses of pigs to a re-challenge with Actinobacillus pleuropneumoniae after being treated with different antimicrobials following their initial exposure.

M Sjölund1, A J Martín de la Fuente, C Fossum, P Wallgren.   

Abstract

Four groups of six specific pathogen-free (SPF) pigs were inoculated intranasally with Actinobacillus pleuropneumoniae serotype 2 and treated with either enrofloxacin, tetracycline or penicillin at the onset of clinical disease, or left untreated. A fifth group was left uninoculated. The inoculated control and the penicillin-treated groups developed severe disease, but the groups treated with enrofloxacin and tetracycline recovered rapidly. All the inoculated pigs, except those treated with enrofloxacin developed serum antibodies to A pleuropneumoniae. On day 28, all five groups were challenged with A pleuropneumoniae without any subsequent treatment. The previously uninoculated control group and the enrofloxacin-treated group developed severe disease, but the three seropositive groups remained unaffected.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411684     DOI: 10.1136/vr.164.18.550

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  3 in total

1.  Field experience with two different vaccination strategies aiming to control infections with Actinobacillus pleuropneumoniae in a fattening pig herd.

Authors:  Marie Sjölund; Per Wallgren
Journal:  Acta Vet Scand       Date:  2010-03-25       Impact factor: 1.695

Review 2.  Haemophilus parasuis: infection, immunity and enrofloxacin.

Authors:  Nubia Macedo; Albert Rovira; Montserrat Torremorell
Journal:  Vet Res       Date:  2015-10-28       Impact factor: 3.683

3.  Exposure to benzylpenicillin after different dosage regimens in growing pigs.

Authors:  Marie Sjölund; Carl Ekstrand; Per Wallgren; Ulf Bondesson; Märit Pringle; Björn Bengtsson
Journal:  Acta Vet Scand       Date:  2020-09-17       Impact factor: 1.695

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.